Современные подходы к применению генерических препаратов: Обзор литературы
Ключевые слова:
генерик, воспроизведенный препарат, оригинальный препарат, КазахстанАннотация
В данной статье рассматриваются актуальные проблемы взаимозаменяемости лекарственных средств, современные подходы к применению оригинальных и генерических препаратов и определение роли генерических препаратов в обеспечении доступности медицинской помощи населению. Анализируется международный опыт, в частности политика отношения к генерическим препаратам в разных странах. Особое внимание уделяется замене противоэпилептических препаратов и биоэквивалентности генериков. По результатам обзора сделаны выводы, что большая часть роста расходов на лекарства будет по-прежнему обусловлена новыми лекарствами. Для некоторых методов лечения, таких как определенные виды иммунотерапии рака, сложный процесс производства означает, что возможности для генерически продуктов по-прежнему ограничены. Тем не менее, во многих странах есть возможности для значительной экономии средств за счет генериков, и даже там, где исторически сложились сильные рынки генериков, регулирующие органы, политики и плательщики могут сделать больше для обеспечения своевременной доступности генериков.
Библиографические ссылки
1. Kodeks Respubliki Kazakhstan. (2020). O zdorov'e naroda i sisteme zdravookhraneniia (Health of the people and the healthcare system) [in Russian]. https://adilet.zan.kz/rus/docs/K2000000360
2. Martsevich, S. Yu., Kutishenko, N. P., & Drapkina, O. M. (2024). Original'nye i vosproizvedennye lekarstvennye preparaty: est' li razlichiia s tochki zreniia klinitsista? (Original and generic drugs: are there any differences from the clinician's point of view?) [in Russian]. Rational Pharmacotherapy in Cardiology, 20(4), 433–443. https://doi.org/10.20996/1819-6446-2024-3088
3. Manzoli, L., Flacco, M. E., Boccia, S., D’Andrea, E., Panic, N., Marzuillo, C., Siliquini, R., Ricciardi, W., & Villari, P. (2016). Generic versus brand-name drugs used in cardiovascular diseases. European Journal of Epidemiology, 31(4), 351–368. https://doi.org/10.1007/s10654-015-0104-8
4. Kesselheim, A. S., Misono, A. S., Lee, J. L., Stedman, M. R., Brookhart, M. A., & Choudhry, N. K. (2008). Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA, 300(21), 2514–2526. https://doi.org/10.1001/jama.2008.758
5. Kesselheim, A. S., Stedman, M. R., Bubrick, E. J., Gagne, J. J., Misono, A. S., Lee, J. L., Brookhart, M. A., & Shrank, W. H. (2010). Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. Drugs, 70(5), 605–621. https://doi.org/10.2165/10898530-000000000-00000
6. Perazzo, H., Castro, R., Luz, P. M., Banholi, M., Goldenzon, R. V., Cardoso, S. W., Grinsztejn, B., & Veloso, V. G. (2020). Effectiveness of generic direct-acting agents for the treatment of hepatitis C: A systematic review and meta-analysis. Bulletin of the World Health Organization, 98(3), 188–197K. https://doi.org/10.2471/BLT.19.231522
7. Howard, J. N., Harris, I., Frank, G., Kiptanui, Z., Qian, J., & Hansen, R. (2018). Factors influencing the use of generic drugs: A systematic review. Research in Social and Administrative Pharmacy, 14(7), 619–627. https://doi.org/10.1016/j.sapharm.2017.08.001
8. Prikaz Ministra zdravookhraneniia Respubliki Kazakhstan. (2021). Ob utverzhdenii pravil obespecheniia lekarstvennymi sredstvami i meditsinskimi izdeliiami v ramkakh garantirovannogo ob"ema besplatnoi meditsinskoi pomoshchi, dopolnitel'nogo ob"ema meditsinskoi pomoshchi litsam, soderzhashchimsia v sledstvennykh izoliatorakh i uchrezhdeniiakh ugolovno-ispolnitel'noi (penitentsiarnoi) sistemy, za schet biudzhetnykh sredstv i (ili) v sisteme obiazatel'nogo sotsial'nogo meditsinskogo strakhovaniia, a takzhe pravil i metodiki formirovaniia potrebnosti v lekarstvennykh sredstvakh i meditsinskikh izdeliiakh v ramkakh garantirovannogo ob"ema besplatnoi meditsinskoi pomoshchi, dopolnitel'nogo ob"ema meditsinskoi pomoshchi litsam, soderzhashchimsia v sledstvennykh izoliatorakh i uchrezhdeniiakh ugolovno-ispolnitel'noi (penitentsiarnoi) sistemy, za schet biudzhetnykh sredstv i (ili) v sisteme obiazatel'nogo sotsial'nogo meditsinskogo strakhovaniia (“On approval of the rules for the provision of medicines and medical devices within the guaranteed volume of free medical care, the additional volume of medical care for persons held in pre-trial detention facilities and institutions of the criminal-executive (penitentiary) system, financed from budgetary funds and/or within the compulsory social health insurance system, as well as the rules and methodology for determining the need for medicines and medical devices within the guaranteed volume of free medical care and the additional volume of medical care for persons held in pre-trial detention facilities and institutions of the criminal-executive (penitentiary) system, financed from budgetary funds and/or within the compulsory social health insurance system). [In Russian]. https://adilet.zan.kz/rus/docs/V2100024069
9. Parkinson, B., Sermet, C., Clement, F., Crausaz, S., & Godman, B. (2015). Disinvestment and value-based purchasing strategies for pharmaceuticals: An international review. PharmacoEconomics, 33(9), 905–924. https://doi.org/10.1007/s40273-015-0293-8
10. Smith, C. (2004). Retail prescription drug spending in the National Health Accounts. Health Affairs, 23(1), 160–167. https://doi.org/10.1377/hlthaff.23.1.160
11. IQVIA Institute for Human Data Science. (2020). Global medicine spending and usage trends: Outlook to 2024. Website. [Cited 5 Mar 2025]. Available from URL: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends
12. Zhai, T. M., Zhang, Y. H., Wan, Q., Liu, Y., & Li, X. (2020). The results and analysis of national health accounts in China in 2018. China Health Economics, 39(6), 5–8. Дои не нашла
13. General Office of the State Council of the People’s Republic of China. (2019). Pilot program for national centralized drug procurement and use. Website. [Cited 5 Mar 2025]. Available from URL: https://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm
14. Haas, J. S., Phillips, K. A., Gerstenberger, E. P., & Seger, A. C. (2005). Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997–2000. Annals of Internal Medicine, 142(11), 891–897. https://doi.org/10.7326/0003-4819-142-11-200506070-00006
15. Aalto-Setälä, V., Kanerva, R. & Bell, J.S. Drug Cost Development of Citalopram and Fluoxetine Following the Introduction of Generic Substitution in Finland. Int J Pharm Med 21, 363–368 (2007). https://doi.org/10.2165/00124363-200721050-00007
16. Yuan, J., Lu, Z. K., Xiong, X. M., & Jiang, B. (2021). Lowering drug prices and enhancing pharmaceutical affordability: An analysis of the National Volume-Based Procurement (NVBP) effect in China. BMJ Global Health, 6(9), e005519. https://doi.org/10.1136/bmjgh-2021-00551
17. Zou, Y., Mao, J., Dong, Y., Yang, L., Dong, W., & Hao, Y. (2024). Affordability of original and generic antihypertensive drugs under the national centralized drug procurement policy and basic medical insurance system: A cross-sectional survey in Xi’an, China. International Journal of Clinical Practice, 2024(1), 4355310. https://doi.org/10.1155/ijcp/4355310
18. Hamada, Y., Uchida, M., Arai, S., Matsumoto, K., & Kamei, M. (2020). Analysis of patients’ request to switch from a generic drug to the original drug in external prescriptions. Journal of Pharmaceutical Health Care and Sciences, 6, 27. https://doi.org/10.1186/s40780-020-00180-w
19. Wouters, O. J., Kanavos, P. G., & McKee, M. (2017). Comparing generic drug markets in Europe and the United States: Prices, volumes, and spending. The Milbank Quarterly, 95(3), 554–601. https://doi.org/10.1111/1468-0009.12279
20. Grabowski, H., Long, G., & Mortimer, R. (2016). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics, 19(9), 836–844. https://doi.org/10.1080/13696998.2016.1176578
21. Bae, M., Shim, S. R., Yang, D. W., Lee, H. J., Kim, S. J., & Kim, J. H. (2025). A five-year analysis of market share and sales growth for original drugs after patent expiration in Korea. Therapeutic Innovation & Regulatory Science. Advance online publication. https://doi.org/10.1007/s43441-025-00741-x
22. Kwon, H.-Y., Kim, H., Lee, J.-Y., Park, S., & Godman, B. (2015). The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Expert Review of Pharmacoeconomics & Outcomes Research, 15(6), 1007–1014. https://doi.org/10.1586/14737167.2015.1085810
23. Kwon, H.-Y., Bae, S., Choi, S.-E., Lee, J.-Y., & Godman, B. (2019). Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea. Health Policy, 123(4), 388–392. https://doi.org/10.1016/j.healthpol.2019.02.004
24. Acosta, A., Ciapponi, A., Aaserud, M., Vietto, V., Austvoll-Dahlgren, A., Kösters, J. P., Vacca, C., Machado, M., & Oxman, A. D. (2014). Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews, (10), CD005979. https://doi.org/10.1002/14651858.CD005979.pub2
25. Galizzi, M. M., Ghislandi, S., & Miraldo, M. (2011). Effects of reference pricing in pharmaceutical markets: A review. PharmacoEconomics, 29(1), 17–33. https://doi.org/10.2165/11537860-000000000-00000
26. Lee, J. L. Y., Fischer, M. A., Shrank, W. H., Polinski, J. M., & Choudhry, N. K. (2012). A systematic review of reference pricing: Implications for US prescription drug spending. American Journal of Managed Care, 18(11), e429–e437.
27. Dunne, S., Shannon, B., Dunne, C., & Cullen, W. (2013). A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacology & Toxicology, 14, 1. https://doi.org/10.1186/2050-6511-14-1
28. Johansen, M. E., & Richardson, C. (2016). Estimation of potential savings through therapeutic substitution. JAMA Internal Medicine, 176(6), 769–775. https://doi.org/10.1001/jamainternmed.2016.1704
29. Greene, J. A. (2014). Generic: The unbranding of modern medicine. Johns Hopkins University Press. Р.391. Jelektronnyj resurs. Rezhim dostupa: https://ru.scribd.com/document/642484502/Generic-The-Unbranding-of-Modern-Medicine-Jeremy-A-Greene-Z-Library-pdf
30. Olsson, P., Pearson, K., Reimers, A., & Källén, K. (2021). Widespread skeptic attitudes among people with epilepsy toward generic antiseizure drugs: A Swedish survey study. Epilepsy & Behavior, 114, 107554. https://doi.org/10.1016/j.yebeh.2020.107554
31. Chaluvadi, S., Chiang, S., Tran, L., Goldsmith, C. E., & Friedman, D. E. (2011). Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia, 52(4), 810–815. https://doi.org/10.1111/j.1528-1167.2011.03025.x
32. Privitera, M. D., Welty, T. E., Gidal, B. E., Diaz, F. J., Krebill, R., Szaflarski, J. P., Dworetzky, B. A., Pollard, J. R., Elder, E. J., Jiang, W., Jiang, Q., & Berg, M. J. (2016). Generic-to-generic lamotrigine switches in people with epilepsy: The randomised controlled EQUIGEN trial. The Lancet Neurology, 15(4), 365–372. https://doi.org/10.1016/S1474-4422(16)00014-4
33. Fanella, M., Morano, A., Fattouch, J., Albini, M., Casciato, S., Manfredi, M., & Giallonardo, A. T. (2017). Switch from originator to equivalent drug in the era of generic antiepileptic drugs: Study of Keppra versus Epitiram clinical equivalence. Clinical Neuropharmacology, 40(6), 239–242. https://doi.org/10.1097/WNF.0000000000000250
34. Reimers, A., Olsson, P., Nilsson, J., Strandberg, M. C., Källén, K., & Tomson, T. (2017). Impact of generic substitution on levetiracetam serum concentration: A prospective study in an outpatient setting. Epilepsy Research, 134, 54–61. https://doi.org/10.1016/j.eplepsyres.2017.04.010
35. Trimboli, M., Russo, E., Mumoli, L., Gagliardi, I., Navarra, M., Gambardella, A., & Labate, A. (2018). Brand-to-generic levetiracetam switching: A 4-year prospective observational real-life study. European Journal of Neurology, 25(4), 666–671. https://doi.org/10.1111/ene.13568
36. Olsson, P., Freij, J., Compagno Strandberg, M., Adelöw, C., Östlund, H., Lindberger, M., & Källén, K. (2021). Physicians’ attitudes toward generic substitutions of antiseizure drugs in epilepsy. Acta Neurologica Scandinavica, 144(5), 600–607. https://doi.org/10.1111/ane.13504
37. Läkemedelsverket. (2019). Läkemedelsbehandling av epilepsi – behandlingsrekommendation. Information från Läkemedelsverket, 30(3), 1–17. Website. [Cited 28 Mar 2025]. Available from URL: https://snpf.barnlakarforeningen.se/wp-content/uploads/sites/4/2020/01/tjugoepilepsirekbakgrund.pdf
38. Berg, M. J., Gross, R. A., Haskins, L. S., Zingaro, W. M., & Tomaszewski, K. J. (2008). Generic substitution in the treatment of epilepsy: Patient and physician perceptions. Epilepsy & Behavior, 13(4), 693–699. https://doi.org/10.1016/j.yebeh.2008.06.001
39. Andrade, C. (2015). Bioequivalence of generic drugs. The Journal of Clinical Psychiatry, 76(9), e1205. https://doi.org/10.4088/JCP.15f10300
40. Andrade, C. (2015). Bioequivalence of generic drugs: A simple explanation for a US Food and Drug Administration requirement. The Journal of Clinical Psychiatry, 76(6), e707. https://doi.org/10.4088/JCP.15f10094
41. Yu, Y., Teerenstra, S., Neef, C., Burger, D. M., Maliepaard, M., & Hekster, Y. A. (2015). Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. European Journal of Clinical Pharmacology, 71(8), 979–990. https://doi.org/10.1007/s00228-015-1878-z
Загрузки
Опубликован
Выпуск
Раздел
Лицензия
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
